
My first blog post! Thank you to my friend, Bess, for reading ahead of time. 11health.com/2020/06/02/the-…

Pediatric GI since 2005. My views are my own! (Who else's would they be?) People won’t care how much you know until they know how much you care

My first blog post! Thank you to my friend, Bess, for reading ahead of time. 11health.com/2020/06/02/the-…

SAIA was proud to partner with ASGE and IBUS to host an Intestinal Ultrasound (#IUS) Workshop, with our very own President, Dr. Bincy Abraham! 🩺 Held on November 6–7 in Downers Grove, Illinois, the workshop brought together healthcare professionals and people living with IBD to help shape the future of GI care. This workshop was an educational session for HCPs looking to learn the techniques behind IUS. Team SAIA aided with the recruitment of patients and healthy controls in addition to putting on a patient panel discussion 💥 A huge thank you to everyone who participated and helped make this event such a success! Together, we're helping advance research and improve the future of paediatric and adult IBD care. Here's a look at some of the highlights! ✨ #SAIA #CultureAndGI

Meet the new iUSCAN Canadian Leadership Council! iuscan.org/canada Today in Toronto: our first FREE IUS training for adult & pediatric GI fellows in Canada—the first step toward IUS certification. Program: iuscan.org/blog/iuscan-launc…

For me- a crucial element of routine Crohn's follow up. IUS and calpro every visit
Thinking of jumping on the intestinal ultrasound bandwagon for IBD? Check out @asaleh_7 & @IBD_Houston study of IUS impact on clinical tx plans and subsequent reduction in active inflammation. Has IUS changed your practice? If not using IUS, why not? bit.ly/42KkZKG

Excited to share that our President @bpabraham was featured alongside @ibdmd and @DrMikeDolinger of @iuscan in this important @EverydayHealth article by on Intestinal Ultrasound (#IUS) & its role in #IBD monitoring: everydayhealth.com/digestive… . SAIA is proud to advocate and create awareness for IUS 👏🏽🙌🏽

My first NEJM paper and it’s featured on their podcast with perfect pronunciation of my name! @CedarsSinai @CedarsSinaiMed podcasts.apple.com/us/podcas…

New for families: our iUSCAN Pediatrics Committee’s illustrated guide helps children, parents & caregivers know what to expect at an intestinal ultrasound visit. Read, download & print for your clinic: iuscan.org/blog/intestinal-u… #IntestinalUltrasound #IBD

So appropriate for the Marriott artwork outside our meeting room to resemble the jejunum! #NASPGHAN2026

A century of IBD drugs. Part 1: the people behind the discoveries. It starts with a post-mortem. London, 1859. Samuel Wilks calls it ulcerative colitis. It was probably Crohn's. Then half a century of a handful of drugs. Sulfasalazine. Steroids. 5-ASA. Thiopurines. Ciclosporin. The first randomised trial in IBD? Cortisone v placebo, Oxford, 1955. Then 1993. Sander van Deventer and his team in Amsterdam give Jan Vilček's anti-TNF antibody in Crohn's for the first time. Infliximab. Everything changes. After that, gut-only vedolizumab, IL-23, JAK inhibitors. But this is really about the people. • Nanna Svartz, Sweden's first woman professor of medicine, designed sulfasalazine. • Gertrude Elion made 6-mercaptopurine and won a Nobel Prize. • Azad Khan, from Bangladesh, showed which half of sulfasalazine actually works. • Andrew Lazarovits made the antibody that became vedolizumab and died at 43, long before it was licensed. • Brian Feagan gave the very first dose of vedolizumab, in London, Ontario, and led the trials from phase 2 to GEMINI 1. He died last November. • Stephan Targan led the first big infliximab trial, then tied TL1A to gut inflammation. We should not forget them. Who did I miss? Part 2 soon: the trials that taught us how to use them.

Intestinal ultrasound versus magnetic resonance enterography for detecting small bowel Crohn's disease in children - Vos - Journal of Pediatric Gastroenterology and Nutrition - Wiley Online Library onlinelibrary.wiley.com/doi/…

Great resource! For #PedsIBD colleagues, the NASPGHAN TDM position paper (Felipez et al, JPGN 2025) addresses children’s faster clearance: higher starting doses, BSA-based dosing <40 kg, and earlier levels in high-risk kids. pmc.ncbi.nlm.nih.gov/article…

Kids with IBD can switch from IV to subcutaneous infliximab and stay well. My meta-analysis of 173 children (6 studies) in Current Gastroenterology Reports: 93% stayed in remission, 92% stayed on drug. The barrier in the US is age-based denials, not the drug. #IBD #PedsIBD link.springer.com/article/10…

Applications are open for iUSCAN’s 2nd IUS Training & Certification cohort at DDW 2027! Free for fellows—and for the first time, spots are available for gastroenterologists & APPs. More details & application on our website: iuscan.org/blog/iuscan-ius-t…

Our iUSCAN Education Committee is building a novel curriculum for intestinal ultrasound training & certification in the US. Congrats to first author/presenter Aaron Balinski: Presidential Poster Award & Outstanding Poster Presenter for our #ACG2026 Phase 1 poster!

Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study academic.oup.com/ibdjournal/…

#Risankizumab in pediatric #Crohn Disease, out now in @JCC_IBD. In 96 children (38% ustekinumab-exposed): steroid-free clinical remission 41% after induction, 50% at weeks 30/54, 90% still on drug at a median 53.5 weeks, no serious safety events. doi.org/10.1093/ecco-jcc/jja… #IBD #pedsIBD #RWE 👏 to all my collaborators on this huge, global effort